Table 3 Association between tumour-stroma ratio combined with BRAF and KRAS mutation status and microsatellite (in)stability, and disease free survival in TNM-stage I–II colon tumours
TSR and BRAF | HR (95% CI) | p-value | |||||
|---|---|---|---|---|---|---|---|
Univariable | |||||||
TSR-Low/BRAF wt | (n = 118, 58.7%) | 1 (reference) | |||||
TSR-Low/BRAF mt | (n = 25, 12.4%) | 3.66 (1.47–9.09) | 0.005 | ||||
TSR-High/BRAF wt | (n = 49, 24.4%) | 2.82 (1.22–6.50) | 0.015 | ||||
TSR-High/BRAF mt | (n = 9, 4.5%) | 4.39 (1.23–15.75) | 0.023 |
TSR and KRAS | HR (95% CI) | p-value | TSR and KRAS | HR (95% CI) | p-value | ||
|---|---|---|---|---|---|---|---|
Univariable | Multivariable* | ||||||
TSR-Low/KRAS wt | (n = 88, 43.8%) | 1 (reference) | TSR-Low/KRAS wt | (n = 88, 43.8%) | 1 (reference) | ||
TSR-Low/KRAS mt | (n = 55, 27.4%) | 0.89 (0.36–2.24) | 0.809 | TSR-Low/KRAS mt | (n = 55, 27.4%) | 0.86 (0.34–2.16) | 0.748 |
TSR-High/KRAS wt | (n = 40, 19.9%) | 2.05 (0.90–4.67) | 0.088 | TSR-High/KRAS wt | (n = 40, 19.9%) | 1.98 (0.87–4.51) | 0.106 |
TSR-High/KRAS mt | (n = 17, 8.5%) | 2.24 (0.80–6.30) | 0.125 | TSR-High/KRAS mt | (n = 17, 8.5%) | 2.15 (0.77–6.04) | 0.146 |
TSR and MSI | HR (95% CI) | p-value | TSR and MSI | HR (95% CI) | p-value | ||
|---|---|---|---|---|---|---|---|
Univariable | Multivariable* | ||||||
TSR-Low/MSS | (n = 115, 57.2%) | 1 (reference) | TSR-Low/MSS | (n = 115, 57.2%) | 1 (reference) | ||
TSR-Low/MSI | (n = 28, 13.9%) | 3.16 (1.27–7.86) | 0.013 | TSR-Low/MSI | (n = 28, 13.9%) | 2.12 (0.77–5.86) | 0.149 |
TSR-High/MSS | (n = 45, 22.4%) | 2.65 (1.13–6.25) | 0.026 | TSR-High/MSS | (n = 45, 22.4%) | 2.46 (1.04–5.83) | 0.041 |
TSR-High/MSI | (n = 13, 6.5%) | 4.29 (1.36–13.47) | 0.013 | TSR-High/MSI | (n = 13, 6.5%) | 3.31 (1.01–10.85) | 0.048 |